N2VC34 Stock Overview
An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NovoCure Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.93 |
| 52 Week High | US$22.30 |
| 52 Week Low | US$5.00 |
| Beta | 0.78 |
| 11 Month Change | -14.69% |
| 3 Month Change | 48.88% |
| 1 Year Change | -49.59% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -75.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| N2VC34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | -13.7% | -0.3% | 2.5% |
| 1Y | -49.6% | -0.4% | -1.4% |
Return vs Industry: N2VC34 underperformed the BR Medical Equipment industry which returned -0.4% over the past year.
Return vs Market: N2VC34 underperformed the BR Market which returned -1.4% over the past year.
Price Volatility
| N2VC34 volatility | |
|---|---|
| N2VC34 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 9.3% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: N2VC34's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine N2VC34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,453 | Asaf Danziger | www.novocure.com |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited Fundamentals Summary
| N2VC34 fundamental statistics | |
|---|---|
| Market cap | R$10.59b |
| Earnings (TTM) | -R$1.05b |
| Revenue (TTM) | R$2.87b |
3.7x
P/S Ratio-10.1x
P/E RatioIs N2VC34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N2VC34 income statement (TTM) | |
|---|---|
| Revenue | US$525.66m |
| Cost of Revenue | US$131.56m |
| Gross Profit | US$394.10m |
| Other Expenses | US$586.84m |
| Earnings | -US$192.74m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.79 |
| Gross Margin | 74.97% |
| Net Profit Margin | -36.67% |
| Debt/Equity Ratio | 158.5% |
How did N2VC34 perform over the long term?
See historical performance and comparison